Transepithelial versus epithelium-off corneal collagen cross-linking for corneal ectasia: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials

Siddharth Nath,1 Carl Shen,2 Alex Koziarz,3 Laura Banfield,4 Mark A Fava,2 William G Hodge5

To cite: Nath S, Shen C, Koziarz A, et al. Transepithelial versus epithelium-off corneal collagen cross-linking for corneal ectasia: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials. BMJ Open 2019;9:e025728. doi:10.1136/bmjopen-2018-025728

Methods and analysis We will include randomised controlled trials (RCTs) comparing transepithelial and epithelium-off CXL for any corneal ectasia. We will search 16 electronic databases including MEDLINE and Embase, as well as the grey literature. Two reviewers will independently screen search results to identify eligible studies, complete data abstraction and conduct quality assessment. We will assess the quality of individual RCTs using the Cochrane risk of bias assessment tool. Our primary outcome will be the change in maximal keratometry at 12 months after treatment, and we will examine 11 additional outcomes. We will summarise our analyses by measures of association (relative risk or odds ratio) and corresponding 95% confidence intervals (CIs) for dichotomous outcomes and weighted mean differences with 95% CIs for continuous outcomes. Prespecified subgroup analyses will be conducted to explore heterogeneity. The overall quality of evidence will be rated using the Grading of Recommendations Assessment, Development and Evaluation approach.

ABSTRACT

Introduction Corneal ectasias are progressive, degenerative ocular diseases defined by abnormal structural changes in the cornea, leading to distortion of vision and substantial reduction in quality of life. Corneal collagen cross-linking (CXL) increases the biomechanical rigidity of the cornea and has been shown to halt ectatic processes. The established CXL protocol requires removal of the corneal epithelium. However, some surgeons have proposed transepithelial approaches to enhance patient recovery and minimise adverse events. Whether novel transepithelial approaches are as effective in arresting ectasia as the established epithelium-off protocol remains unclear. This study will systematically review the evidence on transepithelial CXL approaches and compare it to the epithelium-off protocol.

INTRODUCTION

Corneal ectasias are a group of progressive, degenerative ocular diseases characterised by thinning, bulging and structural changes in the central, paracentral or peripheral cornea, leading to distortion of vision.1 The most common corneal ectasia is keratoconus, and recent estimates from the Netherlands find its prevalence to be as high as 1 in 375.2 Despite considerable research into the genetics and molecular mechanisms underlying ectatic processes, the pathophysiology of these disorders remains poorly understood.3 While many patients with ectasia can be managed with spectacles or rigid gas permeable lenses,
disease-modifying treatments remain sparse, and a subset of patients have disease progression that necessitates a corneal graft.4

Corneal collagen cross-linking (CXL) was first proposed in the late 20th century as a potential disease-modifying intervention for corneal ectasia.4 The aim of CXL is to strengthen the corneal stroma by increasing the number of covalent cross-links between collagen molecules, fibres and microfibrils. This is accomplished by using riboflavin as a photosensitisiser activated by ultraviolet A (UVA) light to create free radicals and induce cross-link formation via the natural lysyl oxidase pathway.4 5 These increased cross-links function to enhance the biomechanical rigidity of the cornea and protect against further thinning and degeneration. Following successful animal and human studies, CXL was approved for treating keratoconus and other corneal ectasias in the early 2000s across Europe and in 2016 in the USA.6 7

The standard approved CXL protocol involves removal of the central 7 mm of corneal epithelium prior to the addition of riboflavin, in order to facilitate sufficient penetration of the compound into the corneal stroma. The cornea is then exposed to UVA light for a predetermined time period to achieve a fluence of 5.4 J/cm² to allow cross-links to form.6 While removal of the corneal epithelium is routine in ophthalmic practice, it carries risks of postoperative infection, is associated with substantial patient discomfort and requires a prolonged recovery period. Recently, transepithelial approaches for loading riboflavin into the corneal stroma have been proposed.8 These protocols aim to sufficiently saturate the cornea with riboflavin in order to facilitate cross-linking without the need to remove the corneal epithelium, and thus, are associated with increased patient comfort and a faster recovery time. Transepithelial approaches also allow for safe treatment of corneas that have thinned beyond the threshold required for epithelium-off CXL, thereby expanding treatment availability to a greater number of patients.

While transepithelial approaches offer significant theoretical benefits, their safety and efficacy in comparison to established epithelium-off protocols remain unclear. Therefore, we will conduct a systematic review and meta-analysis in order to examine transepithelial CXL in comparison to epithelium-off CXL for corneal ectasia. This study protocol has been developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P)9 statement and is registered with the International Prospective Register of Systematic Reviews (PROSPERO).

**METHODS AND ANALYSIS**

We will conduct our systematic review and meta-analysis in agreement with the PRISMA10 11 statement and the Cochrane Collaboration’s Handbook for Systematic Reviews of Interventions guidelines.12 This protocol will be amended and updated as required in line with PRISMA-P criteria9 and updated versions will be made available on PROSPERO with catalogued version history.

**Literature search**

We will conduct a detailed search of the following electronic databases: MEDLINE, Embase, Web of Science, Cochrane CENTRAL, Cochrane DSR, CINAHL, OpenGrey, metaRegister of Controlled Trials, LILACS, ClinicalTrials.gov, WHO Clinical Trials Database, WangFangData, INSPEC, COMPRENDEX, CQVIP and CNKI, from inception through to May 1, 2019. We will use keyword and medical subject heading terms related to corneal ectasia and the cross-linking protocol (transepithelial or epithelium-off) and clinical outcomes. Search strategies will be developed collaboratively by a multidisciplinary research team comprising clinicians, researchers and academic librarians. The search strategy proposed for the MEDLINE database is provided in table 1. The electronic search will be supplemented by manually screening the references of relevant articles, reviewing the proceedings of pertinent meetings and contacting clinical experts in the field. Our search will be conducted without publication type, language or time restrictions.

**Study selection**

Search results will be collated and evaluated independently by two reviewers (SN and CS) against predefined eligibility criteria in order to identify relevant studies (figure 1). Results from all searched databases will be exported as .RIS, .CIW or .XML files containing the complete reference, and EndNote X9 (Clarivate Analytics, Philadelphia, Pennsylvania, USA) will be used for reference management. Reviewers will screen titles and abstracts (level I screening) against prespecified inclusion criteria and complete reports will be retrieved for all references that meet these criteria (level II screening), or where there is any ambiguity. In cases of ambiguity, the full text of the relevant study will be evaluated independently by both reviewers in order to reach a decision on inclusion. We will record the level of agreement between reviewers, and disagreements will be resolved collegially by discussion and consensus, and if needed, including an impartial reviewer (AK) or contacting the study authors. Our inclusion criteria will be as follows:

- **Study design**: randomised controlled trials (including cluster trials and pilot studies) comparing transepithelial and epithelium-off CXL, with no publication type (abstracts vs full articles), time or language restrictions. We will include both completely published reports and conference abstracts in the grey literature. Abstracts will be included only if they fulfil our eligibility criteria and if no follow-up study has been published.
- **Population**: patients of any demographic undergoing CXL for treatment of corneal ectasia following refractive surgery, keratoconus or pellucid marginal degeneration.
- **Intervention**: transepithelial CXL.
Table 1  Search strategy for the MEDLINE electronic database using the Ovid interface

| Database | Search terms |
|----------|--------------|
| Medline 1946–present | 1. Cross-Linking Reagents/2. CORNEA/3. cornea*.mp.4. 1 and (2 or 3)5. ((crosslink* or cross link* or xlink* or x link*) adj3 (cornea* or collagen)).mp.6. CCL.mp.7. CXL.mp.8. C3R.mp.9. 9 or/4–810. Dilatation, Pathologic/11. ectasia*.mp.12. corneal diseases/13. cornea*.mp.14. exp Corneal Dystrophies, Hereditary/15. pellucid marginal degeneration.mp.16. (fuch* adj2 atrophy*).mp.17. ((fuch* or groenouw*) adj2 dystroph*).mp.18. KERATOCONUS/19. keratoconus.mp.20. Corneal Endothelial Cell Loss/21. Corneal Wavefront Aberration/22. keratopathy*.mp.23. or/10–2224. 9 and 2525. ‘Transendothelial and Transepithelial Migration’/26. trans-epithelii*.mp.27. transepitheli*.mp.28. epithelii*.mp.29. (dresden or phototherapeutic or phototherapeutic or iontophoresis or tight junctions).mp.30. or/25–2931. 24 and 3032. remove duplicates from 3133. (accelerat* or nonaccelerat* or conventional or regular or rapid or flash-linking or KXL).mp.34. 24 and 3335. remove duplicates from 34

Control: epithelium-off CXL.

Outcomes: clinical outcomes such as change in maximal keratometry ($K_{\text{max}}$) at 12 months after treatment (primary outcome), incidence of serious adverse events, as well as incidence of disease progression, mean $K_{\text{max}}$ and change in the following: $K_{\text{max}}$ at longest follow-up, mean uncorrected distance visual acuity (UDVA), mean corrected distance visual acuity (CDVA), mean central corneal thickness, mean endothelial cell density, mean intraocular pressure, mean keratometry ($K_{\text{mean}}$) and mean spherical equivalent, at 12 months following treatment.

For studies published more than once (duplicates), we will include only the report with the most informative and complete data. We will exclude observational studies, narrative reviews, systematic reviews, animal studies, letters to the editor and correspondences, as well as randomised trials examining only one CXL modality (transepithelial or epithelium-off) without a comparator. Studies that examine different CXL modalities for indications other than corneal ectasia (eg, bacterial keratitis) will also be excluded. Reasons for excluding studies will be recorded.

Data management and collection

Data from eligible studies will be abstracted independently by two reviewers (SN and CS) and verified for accuracy by a third reviewer (AK). Prior to data collection, the complete articles of all studies meeting our inclusion criteria will be collated, and reviewers will develop and pilot data extraction forms. For studies not published in English, the full article will be translated into English and a clinical expert fluent in the original language of the article will be consulted. Discrepancies in data abstraction will be resolved collegially by deliberation among the two primary reviewers (SN and CS), consulting an independent third reviewer (AK) or contacting the original study authors. Where data in included studies are missing, ambiguous or incomplete, we will contact trial authors for further information and clarification.

We will collect data from eligible studies using forms with the following fields: study first author, year of publication, journal of publication, language, study design, included centres, included countries, number of patients, number of males, number of females, recruitment period, eligibility criteria, method of randomisation, indication for CXL, number of patients in transepithelial and epithelium-off groups, age of patients in transepithelial and epithelium-off groups, procedure for follow-up, number of patients with disease progression 12 months following CXL in transepithelial and epithelium-off groups, $K_{\text{max}}$ before CXL in transepithelial and epithelium-off groups, $K_{\text{max}}$ 12 months after CXL in...
transepithelial and epithelium-off groups, $K_{\text{max}}$ at longest follow-up after CXL in transepithelial and epithelium-off groups, UDVA before CXL in transepithelial and epithelium-off groups, UDVA 12 months after CXL in transepithelial and epithelium-off groups, CDVA before CXL in transepithelial and epithelium-off groups, CDVA 12 months after CXL in transepithelial and epithelium-off groups, central corneal thickness before CXL in transepithelial and epithelium-off groups, central corneal thickness 12 months after CXL in transepithelial and epithelium-off groups, endothelial cell density before CXL in transepithelial and epithelium-off groups, endothelial cell density 12 months after CXL in transepithelial and epithelium-off groups, spherical equivalent 12 months after CXL in transepithelial and epithelium-off groups, $K_{\text{mean}}$ before CXL in transepithelial and epithelium-off groups, $K_{\text{mean}}$ 12 months after CXL in transepithelial and epithelium-off groups, spherical equivalent before CXL in transepithelial and epithelium-off groups, spherical equivalent 12 months after CXL in transepithelial and epithelium-off groups, method for epithelium removal, method for transepithelial riboflavin application, postoperative pain following transepithelial and epithelium-off CXL, time to best UDVA following transepithelial and epithelium-off CXL, time to best CDVA following transepithelial and epithelium-off CXL, time to best UDVA following transepithelial and epithelium-off CXL, UDVA before CXL in transepithelial and epithelium-off groups, UDVA 12 months after CXL in transepithelial and epithelium-off groups, time to best CDVA following transepithelial and epithelium-off CXL, time to best UDVA following transepithelial and epithelium-off CXL, time to best UDVA following transepithelial and epithelium-off CXL, change in UDVA (in logMAR) at 12 months following treatment, change in central corneal thickness (in µM) at 12 months following treatment, change in endothelial cell density (in cells/mm²) at 12 months following treatment, change in intraocular pressure (in mmHg) at 12 months following treatment, change in $K_{\text{mean}}$ (D) at 12 months following treatment, change in spherical equivalent (D) at 12 months following treatment and incidence of serious adverse events (eg, corneal melt, persistent epithelial defects, scarring and persistent stromal haze).

**Data synthesis**

All analyses will be conducted following the intention-to-treat principle using pooled study-level data. For dichotomous outcomes, such as the incidence of ectatic disease progression and the incidence of serious adverse events, we will summarise our analyses by calculating the relative risk (RR) or odds ratio (OR) with corresponding 95% confidence interval (CI). For continuous outcomes, such as the mean $K_{\text{max}}$, change in $K_{\text{max}}$, UDVA, CDVA, central corneal thickness, endothelial cell density, intraocular pressure, $K_{\text{mean}}$ and spherical equivalent, we will determine the weighted mean difference with associated 95% CI. Moreover, we will calculate pooled estimates of all incidences across studies for the transepithelial group, and then separately for the epithelium-off group. The DerSimonian and Laird model will be used to conduct random-effects meta-analysis, and weights will be calculated using the inverse variance method. The threshold for type I error for statistical significance will be $\alpha=0.05$. Between-study heterogeneity will be evaluated using Cochran’s Q test and quantified by the I² statistic, with I² values of 25%–49%, 50%–75% and >75% being graded as low, moderate and high heterogeneity, respectively. Values <25% will not be considered to be heterogeneous.

Publication bias will be evaluated qualitatively by visual examination of funnel plot symmetry and quantified by Begg and Mazumdar’s and Egger’s tests.

We will undertake prespecified subgroup analyses to explore heterogeneity for our primary outcome. Analyses will be performed for subgroups stratified by patient age and sex, CXL protocol (accelerated or non-accelerated) and severity of disease at time of treatment, as well as to compare low versus high risk of bias subgroups. We will conduct sensitivity analysis by performing trial sequential analysis (TSA) to evaluate whether the required information size has been met in order to make a determination of treatment benefit, harm or futility.

The overall evidence will be summarised using the Grading of Recommendations Assessment, Development and Evaluation approach. Evidence will be assessed for the domains of risk of bias, consistency, precision, reporting bias, directness and other bias. The evidence for each outcome will be ranked as being of high, moderate, low or very low quality.

Statistical analyses will be conducted using Comprehensive Meta-analysis V.3.3.070 (Biostat, Englewood, New Jersey, USA), and TSA will be performed using Trial
Sequential Analysis V.0.9.5.10 Beta (Copenhagen Trial Unit, Copenhagen, Denmark).

Patient and public involvement
The outcomes selected for analysis were informed by examining surveys on corneal ectasia and patient experience. Our outcomes are directly linked to the quality of vision following CXL as well as the incidence of complications and adverse effects. While our review protocol did not have direct patient involvement, we expect the results of our review to substantially impact the lived experience of patients with corneal ectasia and their outcomes following CXL.

ETHICS AND DISSEMINATION
Research ethics board approval is not required for this study as it evaluates data from previously published trials. As such, there are no concerns of patient privacy or informed consent. The results of this review are expected to substantially inform clinical practice, future research and the management of patients with corneal ectasia. By comprehensively examining the evidence on CXL treatment approaches, this study is expected to influence how clinicians perform this evolving procedure, and potentially improve patient outcomes. Findings from this review will be submitted to a peer-reviewed journal for publication and will be presented widely at conferences and seminars.

Author affiliations
1Division of Ophthalmology, Department of Surgery and Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada
2Division of Ophthalmology, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
3Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
4Health Sciences Library, McMaster University, Hamilton, Ontario, Canada
5Department of Ophthalmology, Ivey Eye Institute and Department of Clinical Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada

Contributors SN and CS conceived and designed the study. SN and LB developed the search strategy and SN, LB and CS piloted it in relevant databases. SN and CS developed the review protocol, selection criteria, risk of bias assessment strategy and data management procedures. SN, CS, AK and JK established the data synthesis approach. SN, CS, AK, LB, MAF and WGH critically revised and commented on the intellectual content of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES
1. Maharana PK, Dubey A, Jhanji V, et al. Management of advanced corneal ectasias. Br J Ophthalmol 2016;100:34–40.
2. Goddeeris BA, de Wit GA, Uiterwaal CS, et al. Age-specific incidence and prevalence of Keratoconus: A Nationwide Registration Study. Am J Ophthalmol 2017;175:169–72.
3. Romero-Jiménez M, Santodomingo-Rubido J, Wolffsohn JS. Keratoconus: a review. Cont Lens Anterior Eye 2010;33:157–66.
4. Spoerl E, Huhle M, Seiler T. Induction of cross-links in corneal tissue. Exp Eye Res 1997;65:97–103.
5. O’Brart DP. O’Brart DPS. Corneal collagen cross-linking: a review. J Optom 2014;7:113–24.
6. Wöllensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol 2003;135:620–7.
7. Mohammadpour M, Masoumi A, Mirghorbani M, et al. Updates on corneal collagen cross-linking: Indications, techniques and clinical outcomes. J Curr Ophthalmol 2017;29:235–47.
8. Filippello M, Stagni E, et l’Institut. Treatment modalities in corneal collagen crosslinking: bilateral study. J Cataract Refract Surg 2012;38:283–91.
9. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.
10. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
11. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
12. Cochrane handbook for systematic reviews of interventions. 5.1.0 ed. The Cochrane Collaboration 2011.
13. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
15. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
16. Beggs CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.
17. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
18. Brok J, Thorlund K, Gluud C, et al. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 2008;61:763–9.
19. Wettenslo J, Thorlund K, Brok J, et al. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008;61:64–75.
20. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.